These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31827111)

  • 21. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.
    Lou Y; McDonald PC; Oloumi A; Chia S; Ostlund C; Ahmadi A; Kyle A; Auf dem Keller U; Leung S; Huntsman D; Clarke B; Sutherland BW; Waterhouse D; Bally M; Roskelley C; Overall CM; Minchinton A; Pacchiano F; Carta F; Scozzafava A; Touisni N; Winum JY; Supuran CT; Dedhar S
    Cancer Res; 2011 May; 71(9):3364-76. PubMed ID: 21415165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
    J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
    Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
    Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
    Lau J; Zhang Z; Jenni S; Kuo HT; Liu Z; Vullo D; Supuran CT; Lin KS; Bénard F
    Mol Pharm; 2016 Mar; 13(3):1137-46. PubMed ID: 26866675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
    Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Rücker G; Weber WA; Meyer PT; Werner M; Grosu AL; Kayser G
    Acta Oncol; 2016 Nov; 55(11):1299-1304. PubMed ID: 27593107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
    Krall N; Pretto F; Mattarella M; Müller C; Neri D
    J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical Characterization of DPI-4452: A
    Massière F; Wiedemann N; Borrego I; Hoehne A; Osterkamp F; Paschke M; Zboralski D; Schumann A; Bredenbeck A; Brichory F; Attinger A
    J Nucl Med; 2024 May; 65(5):761-767. PubMed ID: 38514083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.
    Ellingsen C; Andersen LM; Galappathi K; Rofstad EK
    BMC Cancer; 2015 Oct; 15():805. PubMed ID: 26502718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: correlation between primary and xenograft tumors.
    Stegeman H; Rademakers SE; Span PN; Takes RP; van der Kogel AJ; Kaanders JH; Bussink J
    Head Neck; 2014 Sep; 36(9):1288-95. PubMed ID: 24668936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
    van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
    Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
    Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
    Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [(18)F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models.
    Peeters SG; Dubois L; Lieuwes NG; Laan D; Mooijer M; Schuit RC; Vullo D; Supuran CT; Eriksson J; Windhorst AD; Lambin P
    Mol Imaging Biol; 2015 Oct; 17(5):615-9. PubMed ID: 25708744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
    Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer.
    van Brussel AS; Adams A; Oliveira S; Dorresteijn B; El Khattabi M; Vermeulen JF; van der Wall E; Mali WP; Derksen PW; van Diest PJ; van Bergen En Henegouwen PM
    Mol Imaging Biol; 2016 Aug; 18(4):535-44. PubMed ID: 26589824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with
    van Oostenbrugge TJ; Langenhuijsen JF; Oosterwijk E; Boerman OC; Jenniskens SF; Oyen WJG; Fütterer JJ; Mulders PFA
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1864-1870. PubMed ID: 31768601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
    Faes S; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Datta D; Demartines N; Dormond O
    Oncotarget; 2016 Jun; 7(24):36666-36680. PubMed ID: 27153561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
    van Brussel AS; Adams A; Vermeulen JF; Oliveira S; van der Wall E; Mali WP; van Diest PJ; van Bergen En Henegouwen PM
    Breast Cancer Res Treat; 2013 Jul; 140(2):263-72. PubMed ID: 23860929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.